Human Smallpox Disease — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for human smallpox disease. 6 active patents protecting 1 drugs from 1+ originators. First major cliff: 2031. Daily refresh.

1
Approved drugs
6
Active US patents
51/100
Avg vulnerability
—
Annual revenue covered

Originators in Human Smallpox Disease

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Emergent Biodefense 6 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating human smallpox disease. Each bar = one year. Y-axis scaled to peak year (4 patents).

2
31
4
34

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Tembexa
BRINCIDOFOVIR
 Emergent Biodefense 6 51 — 2031-08-31

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9303051 Tembexa method of use 68 2031-08-31
9303051 Tembexa method of use 68 2031-08-31
10112909 Tembexa method of use 62 2034-10-10
10487061 Tembexa method of use 62 2034-10-10
9371344 Tembexa formulation 42 2034-10-10
8962829 Tembexa composition of matter 4 2034-10-10

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8962829 Tembexa composition of matter 4 2034-10-10
9371344 Tembexa formulation 42 2034-10-10
10112909 Tembexa method of use 62 2034-10-10
10487061 Tembexa method of use 62 2034-10-10
9303051 Tembexa method of use 68 2031-08-31
9303051 Tembexa method of use 68 2031-08-31

Related